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Regulation of Blood Pressure During
Long-Term Ouabain Infusion in
Long-Evans Rats
Jingli Wang, Aldo Tempini, Bruno Schnyder, and Jean-Pierre Montani
We tested whether ouabain, an inhibitor of the
sodium pump, can lead to chronic hypertension in
Long-Evans rats using sensitive 24-h measurements
of blood pressure. After a control week of vehicle
isotonic saline infusion (14.4 mL/day), ouabain was
infused intravenously at 30 mg/kg/day in intact
(2K) and uninephrectomized (1K) Long-Evans rats
for a total of 4 weeks. Although plasma ouabain
concentration rose to 0.97 6 0.15 nmol/L with
ouabain infusion, mean arterial pressure did not
change in either 2K (D 5 20.6 6 1.3 mm Hg) or 1K
(D 5 21.2 6 0.7 mm Hg) rats. These data suggest
that Long-Evans rats are insensitive to the
hypertensive effects of ouabain. Am J Hypertens
1999;12:423–426 © 1999 American Journal of
Hypertension, Ltd.
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An endogenous ouabain-like inhibitor ofthe Na1,K1-ATPase pump has been im-plicated in the pathogenesis of manyforms of experimental hypertension, espe-
cially in volume-dependent hypertension,1 through
the following mechanism. Inhibition of the sodium
pump raises intracellular calcium concentration in
vascular smooth muscle cells, via both membrane de-
polarization and reduction in the Na1/Ca21 ex-
change, resulting in vasoconstriction. It has been
claimed that endogenous ouabain exhibits physiologic
and biochemical activities indistinguishable from
plant-derived ouabain.2 Thus, if endogenous ouabain
plays an important role in blood pressure control,
administration of exogenous ouabain at a dose that
mimics elevated plasma levels found in hypertension
should raise blood pressure.
Indeed, several experimental studies have shown
that exogenous ouabain can increase blood pressure in
rats.3–6 Other studies, however, have failed to demon-
strate a hypertensive effect of ouabain in rats,7–9
sheep,10 dogs,11 and humans.12 The diverging results
in rats could be linked to differences in the doses and
duration of ouabain administration in the strains used
or in the methods used for blood pressure measure-
ment. In fact, blood pressure is often measured in rats
in conditions of stress, by tail-cuff techniques, or for
short recording periods during recovery from surgery
and anesthesia. The continuous monitoring of arterial
pressure 24 h a day, a technique that is very sensitive
to small changes in blood pressure,13 may help to
resolve this issue. Therefore, to further test the role of
an endogenous ouabain-like substance in blood pres-
sure control, we infused ouabain in Long-Evans rats at
a dose known to elevate blood pressure in some stud-
ies3–6 (30 mg/kg/day intravenous [iv] for 28 days)
while measuring arterial pressure 24 h a day. Further-
more, we also tested whether reduction in renal mass,
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a procedure that reduces the kidney’s ability to excrete
salt and water, can potentiate the pressor effect of
ouabain.
MATERIALS AND METHODS
Animal Preparation Male Long-Evans rats (body
weight, 350–450 g; 12–24 weeks old) supplied by the
R. Janvier Center (Le Genest-St-Isle, France) were used
in this study. All protocols were approved by the State
Animal Committee. Using sodium pentobarbital anes-
thesia and aseptic techniques, the rats were instru-
mented with arterial and venous catheters inserted
into the left jugular vein and the abdominal aorta (via
laparotomy), respectively. In some rats, the left kidney
was removed during the same procedure. The cathe-
ters were tunneled subcutaneously to the scapular
region, exteriorized, protected by a flexible coiled steel
spring, and connected to a double channel swivel
(Instech Laboratories, Plymouth Meeting, PA). The
rats were housed in individual metabolic cages, in a
room maintained at constant temperature (22°C) with
a 12-h light-dark cycle. The venous line was connected
to a syringe pump (Kent Scientific, Litchfield, CT). The
arterial line was flushed daily, filled with heparin
(1000 USP/mL), and connected to a COBE (Lakewood,
CO) CDX-III pressure transducer mounted on the cage
at animal level. Sodium intake was fixed at about 5
mmol/day using food (25 g rat chow with 0.3% so-
dium) and isotonic saline intravenous infusion
(14.4 mL/day). Free access was available to tap water.
Experimental Protocol After at least 10 days of re-
covery from surgery followed by a control period of 7
days of saline vehicle infusion, ouabain (Sigma Chem-
ical Corp., St. Louis, MO) was started at 30 mg/kg/day
(10 mL/min) in both intact (2K) and uninephrecto-
mized (1K) rats for a total of 4 weeks. All solutions
were prepared aseptically and infused through a Mil-
lipore filter (0.22 mm, Sterivex-GP, Millipore, Bedford,
MA). Additional 2K and 1K rats served as time con-
trols, receiving only the isotonic saline infusion. Daily
urine samples and biweekly blood samples (0.7 mL)
were collected for creatinine and electrolyte analysis.
Continuous Hemodynamic Monitoring The pul-
satile arterial pressure signal was sent to an
analog-digital converter (CIO-DAS08, Computer-
Boards, Mansfield, MA) and analyzed by computer
using customized software for beat-to-beat analysis.13
The analog signal was sampled at 500 Hz, for 5-s
periods every 30 s, for 22 h daily (from 10 am to 8 am
the next day). For each rat, the daily mean arterial
pressure and heart rate were thus computed as the
average of 2640 sampling periods, and weekly results
are reported as the average of 7 consecutive days.
Analytical Measurements Sodium, potassium, and
creatinine concentrations of urine and blood samples
were measured by flame photometry (model IL 943,
Instrumentation Laboratories, Lexington, MA) and by
the kinetics of Jaffe´ (Beckman creatinine analyzer 2,
Fullerton, CA), respectively. At the end of the exper-
iments, a 5-mL arterial blood sample was collected in
EDTA tubes for measurement of plasma ouabain con-
centration in duplicate by enzyme immunoassay (Du-
Pont Ouabain EIA kit, DuPont, Boston, MA).
Statistical Analysis The data were analyzed by anal-
ysis of variance for repeated measurements and Dun-
nett’s multiple comparison t test when applicable. Sta-
tistical significance was taken as P , .05. All data are
expressed as mean 6 SEM.
RESULTS
During the 5 weeks of observation, food and water
intake, 24-h urinary sodium and potassium excretion,
plasma sodium and potassium concentration, and glo-
merular filtration rate remained stable and were un-
affected by the ouabain infusion. As shown in Figure
1, mean arterial pressure did not change throughout
the ouabain infusion. Control values were 98.4 6 1.9
mm Hg in 2K rats (n 5 5) and 99.4 6 1.3 mm Hg in 1K
rats (n 5 5), and values during the fourth week of
ouabain infusion were 97.9 6 1.8 mm Hg in 2K rats
and 98.2 6 0.6 mm Hg in 1K rats. Heart rate was also
unaffected by the ouabain infusion. In 2K rats heart
rate was 338 6 14 beats/min during the control week
and 331 6 9 beats/min during the fourth week of
ouabain infusion. In 1K rats heart rate was 342 6 24
beats/min during the control week and 341 6 12
beats/min during the fourth week of ouabain infu-
sion. Plasma ouabain concentrations measured at the
end of the experiment were 0.02 6 0.002 nmol/L in
time-control rats (2K11K), 0.93 6 0.17 nmol/L in 2K
ouabain rats, and 1.02 6 0.26 nmol/L in 1K ouabain
rats (or 0.97 6 0.15 nmol/L when 2K and 1K data are
pooled).
DISCUSSION
The major finding of the present study is that exoge-
nous ouabain infused for 4 weeks, at a dose that raises
plasma ouabain concentration in the nanomolar range,
had no effect on systemic blood pressure or heart rate
in Long-Evans rats, even under conditions of reduced
renal mass and slightly elevated sodium intake ('5
mmol/day). Although endogenous ouabain is struc-
turally indistinguishable from plant-derived ouabain
by mass spectrometry,2 a possible limitation of our
study is that endogenous ouabain could be an isomer
of ouabain and may produce a more profound inhibi-
tion of vascular smooth muscle sodium pump iso-
forms. However, in preliminary experiments from our
laboratory, we have been unable to observe changes in
blood pressure with a higher infusion rate of ouabain
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(150 mg/kg/day for 28 days) in uninephrectomized
Long-Evans rats (n 5 4). A major strength of our study
is that arterial pressure was measured 24 h a day in
conscious undisturbed animals, a method that pro-
vides highly reproducible values from day to day13
and is thus very sensitive to small changes in blood
pressure. Our data therefore strongly suggest that
Long-Evans rats are resistant to the hypertensive ef-
fects of ouabain.
The role of an endogenous ouabain-like inhibitor of
the Na1,K1-ATPase pump in blood pressure control
remains controversial. Several studies have reported
an increase in blood pressure with ouabain in different
strains of rats. For example, Manunta et al3 infused
ouabain at different doses (3, 10, and 30 mg/kg/day
subcutaneously for 5 weeks by osmotic minipumps) in
normal Sprague-Dawley rats maintained under a nor-
mal salt intake and found a dose-dependent increase
in blood pressure measured once a week using the
tail-cuff method. Similarly, Kurashina et al6 injected
ouabain (27.8 mg/kg/day intraperitoneally for 6
weeks) in Sprague-Dawley rats with a high salt intake
and found an elevation of blood pressure measured
with an indwelling catheter using anesthesia. An in-
crease in blood pressure was also found in Wistar rats,
whether ouabain was injected intraperitoneally4 (27.8
mg/kg/day for 28 days; BP measured by the tail-cuff
method), infused5 (10 mg/day), or released from sub-
cutaneously implanted pellets5 (25–75 mg/day for 2
weeks; BP measured by indwelling catheter during
recovery from surgery and anesthesia).
In contrast, other studies in Sprague-Dawley rats
have reported no change in blood pressure (measured
by tail cuff) with ouabain administration.7–9 Some of
these studies8,9 have been criticized because ouabain
was administered at higher doses or for too short a
period. High doses of ouabain can cause cardiotoxicity
and sensitize arterial baroreceptor,5 and could there-
fore attenuate the responses to ouabain. Although this
could explain the negative results of Nirasawa et al9
(ouabain 1, 5, or 10 mg/kg/day intraperitoneally for
26 days) and Yasujima et al8 (ouabain 1.2 mg/kg/day
iv for 6 days), Li et al7 infused ouabain at much lower
doses (10 to 100 mg/kg/day intraperitoneally by os-
motic minipumps for 28 days) and were unable to
detect any change in arterial blood pressure.
Adding to the controversy is the method of blood
pressure measurement. All rat studies mentioned here
report recordings of blood pressure for short periods
only, often in the conditions of possible stress related
to tail-cuff measurement, which involves heating and
restraint, or measurements with indwelling catheters
during or shortly after surgery and anesthesia. This
may lead to increased background noise in blood pres-
sure measurements and possibly to conflicting results.
In our study the animals were allowed to recover for
at least 10 days after surgery, and blood pressure was
measured 24 h a day in the conscious undisturbed
animal, a method that should detect very small
changes in blood pressure.13
However, because we used a different strain of rats
(Long-Evans), our study does not exclude the possi-
bility that an endogenous ouabain-like substance may
play a role in long-term blood pressure control of
Wistar or Sprague Dawley rats. Some authors have
reported that Long-Evans rats are less sensitive to
certain hypertensive agents, such as chronic cold ex-
posure14 and sucrose loading.15 However, unine-
phrectomy increases blood pressure markedly during
sucrose loading.15 Furthermore, Long-Evans rats do
not seem to be resistant to mineralocorticoid-induced
hypertension, as mineralocorticoid administration
FIGURE 1. Effects of a 4-week infusion of ouabain (ouabain
group) or isotonic saline vehicle (time-control group) on mean
arterial pressure in intact 2K rats (A) and in uninephrectomized
1K rats (B) following a first week of control saline infusion
(control week). WK, week. Data are expressed as mean 6 SEM.
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leads to similar increases in blood pressure in Long-
Evans rats, compared with Sprague Dawley rats.16
Nevertheless, we cannot exclude the possibility that
Long-Evans rats may have a different distribution of a
isoforms of the sodium pump in comparison to other
rat species. Long-Evans rats could have a greater pro-
portion of the a 1 isoform in their vascular smooth
muscle, an isoform that is particularly resistant to
ouabain.17 Further experiments remain necessary to
test this possibility.
In summary, our data suggest that long-term infu-
sion of ouabain that yields plasma concentrations in
the nanomolar range is unable to raise arterial pres-
sure in conscious Long-Evans rats, even under condi-
tions of reduced renal mass and a slight increase in
sodium intake. In conclusion, an endogenous ouabain-
like inhibitor of the Na1,K1-ATPase pump does not
seem to play an important role in long-term blood
pressure control in Long-Evans rats.
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